Less than a week before Ipsen’s palovarotene was due to go in front of an FDA advisory committee, the meeting has been called off following a request by the regulator for more data.
It’s the latest twist in the turbulent tale of the ultra-rare disease therapy – developed to treat genetic disorder fibrodysplasia ossificans progressiva (FOP) – which has seen is progress to the US market held up by a series of clinical and regulatory obstacles.
In the latest setback, a 31 October Endocrinologic and Metabolic Drugs Advisory Committee meeting has been cancelled and postponed to a later, undecided date, giving the FDA time to see data from a clinical trial that according to the French drugmaker “does not relate to the safety profile of palovarotene.”
The company said in a statement it is currently working to fulfil the request and will “work expediently with the FDA as we remain committed to bringing innovative treatment options to the [FOP] community.”
Palovarotene has been approved in Canada under the Sohonos brand name for both chronic use and flare-ups in FOP, a genetic disorder in which tendons and ligaments gradually become more bone-like, but making progress in the US and other world markets has been challenging.
The drug failed a futility test in a pivotal trial and was also placed under a partial clinical hold by the FDA while it probed the drug’s safety.
Then, Ipsen was forced to withdraw its marketing application for the drug in the US last summer after a request for more data from its phase 3 trial programme, which also delayed regulatory filings in Europe and elsewhere.
The implications of the latest FDA request are not yet clear, but even a short delay will be frustrating for Ipsen as it tries to bring a therapy for FOP to market in the US ahead of its main rival Regeneron.
Regeneron’s activin A-targeting antibody garetosmab is due to start a phase 3 trial imminently after showing preliminary efficacy in a phase 2 trial reported in 2020, but has also been delayed by an FDA clinical hold after fatalities were seen in the study.
Garetosmab has a different mechanism of action to Ipsen’s drug, which works as a selective retinoic-acid receptor gamma (RARγ) and is administered intravenously every four weeks while palovarotene is dosed orally once-daily.
Palovarotene was acquired by Ipsen under the tenure of its former chief executive David Meek as part of its $1 billion upfront acquisition of Clementia Pharma in 2019. Ipsen meanwhile also has another FOP candidate in its portfolio via its $535 million agreement with Blueprint in 2019 for BLU-782, an ALK2 inhibitor.
Ipsen meanwhile also has another FOP candidate in its portfolio via its $535 million agreement with Blueprint in 2019 for BLU-782, an ALK2 inhibitor. The disorder leads to impaired movement as well as difficulty opening the mouth, affecting eating and speaking, and preventing normal breathing.
This post was originally published on Source Link